Neuroprotection after oxygen shortage in the brain


Neurophyxia is an innovative clinical-stage drug development company, developing novel drugs to reduce the deleterious effects of oxygen shortage in the brain.

Our lead product 2-IB  is currently in Phase IIb/III Clinical  Development. Our primary focus is on Stroke. Additional indications include Birth Asphyxia and Cardiac Arrest.